Compare peptides side-by-side
Pick any two peptides to compare their evidence quality, FDA approval status, research scores, risks, and indications. All data sourced from the SmartPeptide library.
Educational only — not medical advice. SmartPeptide does not prescribe, diagnose, or treat. Always consult a licensed healthcare provider before using any peptide, supplement, medication, or protocol.
Sermorelin
GHRH analog (first 29 amino acids of human GHRH). Stimulates endogenous growth hormone release. Approved for pediatric GH deficiency, widely used off-label in adults.
Full pagePediatric GH deficiency: FDA approved (now discontinued for marketing in the US but evidence stands). Stimulates GH/IGF-1 release in healthy adults short-term.
Adult anti-aging use, body recomposition, and long-term safety. Most clinic-marketed indications are NOT FDA-approved.
Hyperglycemia, fluid retention, hypothyroidism risk, possible carpal tunnel symptoms. Long-term cancer risk theoretical but understudied.
Injection-site reactions, headache, flushing, transient sleepiness, dizziness.
SS-31 (Elamipretide)
Stealth BioTherapeutics' mitochondria-targeted tetrapeptide. Binds cardiolipin in the inner mitochondrial membrane and improves electron transport chain efficiency. Multiple Phase 3 trials in genetic mitochondrial diseases (Barth syndrome, primary mitochondrial myopathy) with mixed regulatory outcomes.
Full pagePhase 3 trials in Barth syndrome and primary mitochondrial myopathy show meaningful improvements in muscle function in specific subgroups. Heart failure trials had mixed results. FDA approval status varies by indication and is evolving.
Use outside FDA-recognized genetic mitochondrial diseases is experimental. Anti-aging / longevity applications are extrapolated from mechanism + animal data, not from RCTs in healthy adults.
Injection-site reactions (notable in trials). Headache, GI symptoms. Long-term safety being characterized. FDA has issued complete-response letters on prior submissions — efficacy outside specific genetic indications remains debated.
Injection-site erythema (common), headache, nausea, dizziness, fatigue.